Our results demonstrate the PERK/eIF2α/ATF4 activity within VSMCs may be an attractive therapeutic target for AAAs, as it can prevent smooth muscle dysfunction and decrease pathological vascular remodeling. The gene discussed is EIF2AK3; the disease is achalasia-alacrima syndrome.